What Is a Normal A1C? Blood Sugar Ranges, Morning Highs, and When to Act

What Does A1C Actually Measure?

A1C, also called HbA1c or glycated hemoglobin, measures the percentage of hemoglobin proteins in your red blood cells that have glucose attached to them. Because red blood cells live roughly 90 days, the A1C result gives a 3-month average picture of blood sugar control rather than a single-point snapshot. One blood draw replaces what would otherwise require weeks of daily glucose logs.

The American Diabetes Association (ADA) defines a normal A1C as below 5.7%, prediabetes as 5.7% to 6.4%, and diabetes as 6.5% or higher, confirmed on a second test on a different day unless symptoms and a random glucose above 200 mg/dL are present [1]. These thresholds come from epidemiological data linking A1C levels to the risk of developing diabetic retinopathy, the microvascular complication used as a biological anchor for diagnostic cut-points.

A1C is not a perfect test. Conditions that shorten red blood cell lifespan, such as hemolytic anemia or sickle cell disease, will artificially lower the result. Pregnancy can also distort readings. In these populations, fasting plasma glucose or a 2-hour oral glucose tolerance test (OGTT) is preferred [1].

The ADA's Standards of Medical Care in Diabetes, 2024 states: "For most nonpregnant adults with diabetes, an A1C goal of less than 7% is appropriate." [1] Individualized targets between 7% and 8% may be acceptable for older patients with limited life expectancy or a high burden of hypoglycemia risk.

Here is a quick reference for how A1C maps to estimated average glucose (eAG):

• A1C 5.7% corresponds to approximately 117 mg/dL eAG
• A1C 6.5% corresponds to approximately 140 mg/dL eAG
• A1C 7.0% corresponds to approximately 154 mg/dL eAG
• A1C 8.0% corresponds to approximately 183 mg/dL eAG
• A1C 10.0% corresponds to approximately 240 mg/dL eAG

The formula is eAG (mg/dL) = (28.7 x A1C) minus 46.7, validated in the A1C-Derived Average Glucose (ADAG) study [2].

What Are Normal Fasting and Postprandial Blood Sugar Levels?

Fasting glucose below 100 mg/dL is normal. Between 100 and 125 mg/dL is impaired fasting glucose, which places a person in the prediabetes category. A fasting reading at or above 126 mg/dL on two occasions meets the ADA diagnostic threshold for type 2 diabetes [1].

Two-hour postprandial (after-meal) targets differ by population. For people without diabetes, glucose typically peaks below 140 mg/dL and returns to baseline within 2 hours. For people with diagnosed diabetes, the ADA recommends a postprandial goal below 180 mg/dL at the 1- to 2-hour mark, although tighter targets are used in pregnancy [1].

Continuous glucose monitors (CGMs) have added a new metric: time in range (TIR). The consensus target is more than 70% of readings between 70 and 180 mg/dL in adults with type 1 or type 2 diabetes, with less than 4% of readings below 70 mg/dL [3]. A 2019 analysis published in Diabetes Care (N=105) showed that each 10% increase in TIR corresponded to a 0.5 percentage point reduction in A1C [3], which helps clinicians translate CGM data into a familiar metric.

Random glucose testing also has diagnostic value. A random plasma glucose above 200 mg/dL accompanied by classic symptoms, such as polyuria, polydipsia, or unexplained weight loss, is sufficient to diagnose diabetes without a second confirmatory test [1].

What Is a Dangerous Blood Sugar Level?

Two ends of the glucose spectrum require urgent attention. On the low end, hypoglycemia is classified in three levels by the ADA and Endocrine Society. Level 1 is glucose below 70 mg/dL, alerting the person to take action. Level 2 is glucose below 54 mg/dL, which is clinically significant regardless of symptoms. Level 3 is any hypoglycemic event severe enough to require outside assistance [4].

Symptoms at Level 1 include shakiness, sweating, and rapid heartbeat. Below 54 mg/dL, cognitive impairment, seizure, and loss of consciousness become real risks [4]. Untreated severe hypoglycemia can cause cardiac arrhythmia and death.

On the high end, persistent readings above 240 mg/dL signal ketoacidosis risk in people with type 1 diabetes or insulin-deficient type 2. Diabetic ketoacidosis (DKA) carries a mortality rate of approximately 0.2% to 2% in well-resourced settings and higher in low-resource environments [5]. Hyperglycemic hyperosmolar state (HHS), more common in type 2 diabetes, can develop at glucose levels above 600 mg/dL and carries a mortality rate of 10% to 20% [5].

For people managing diabetes at home, the FDA-cleared guidance is to call a provider or go to an emergency department if glucose exceeds 300 mg/dL on two consecutive readings, urine ketones are moderate or large, or vomiting prevents oral intake of fluids [5].

Why Is Blood Sugar Higher in the Morning? Understanding the Dawn Phenomenon

Morning blood sugar is higher than expected in a large proportion of people with diabetes, and it has a specific physiological cause. Cortisol, growth hormone, glucagon, and epinephrine all surge in the early morning hours, typically between 2 a.m. and 8 a.m. This hormonal wave signals the liver to release stored glucose through glycogenolysis and gluconeogenesis, a process called the dawn phenomenon [6].

The elevation is not trivial. A study in Diabetes Care found that dawn phenomenon contributed an average rise of 30 to 40 mg/dL in people with type 2 diabetes who were otherwise well controlled overnight [6]. In people without diabetes, compensatory insulin secretion blunts this rise. In people with type 2 diabetes, that compensatory response is blunted or absent.

A second mechanism, the Somogyi effect, is worth distinguishing from dawn phenomenon. The Somogyi effect is a rebound hyperglycemia following unrecognized overnight hypoglycemia. The body's counter-regulatory hormones over-correct, driving glucose sharply upward by morning. It is less common than dawn phenomenon but more dangerous because the underlying low goes unnoticed [6].

How do you tell them apart? A CGM trace solves this clearly. If glucose drifts steadily upward from roughly 3 a.m. onward, that is dawn phenomenon. If glucose drops below 70 mg/dL between 2 a.m. and 4 a.m. before rebounding, Somogyi is the more likely cause.

Management strategies differ accordingly. For dawn phenomenon, options include taking basal insulin at bedtime instead of morning, switching to a longer-acting basal analog such as insulin degludec (Tresiba), or, in people using closed-loop pump systems, allowing the algorithm to increase basal delivery around 3 a.m. [7]. Metformin reduces hepatic glucose output and can blunt dawn phenomenon in people with type 2 diabetes or prediabetes [7]. Exercise the evening before modestly reduces fasting glucose the following morning, with a 2023 meta-analysis in Diabetologia (N=2,400 across 37 trials) finding that resistance training performed in the afternoon lowered fasting glucose by an average of 5.4 mg/dL compared to morning sessions [8].

For Somogyi-driven morning highs, the fix is reducing the overnight insulin dose or adjusting the basal rate on a pump to prevent the initial dip.

What Is Prediabetes and How Serious Is It?

Prediabetes affects an estimated 98 million American adults, roughly 38% of the adult population, according to 2024 CDC data [9]. Despite being labeled "pre," it carries its own risks. Prediabetes is associated with early microvascular injury, a 50% increase in cardiovascular event risk, and, without intervention, a 5% to 10% annual rate of progression to type 2 diabetes [9].

The diagnostic criteria are:

• Fasting plasma glucose of 100 to 125 mg/dL (ADA) or 110 to 125 mg/dL (WHO)
• 2-hour OGTT glucose of 140 to 199 mg/dL
• A1C of 5.7% to 6.4% (ADA) or 6.0% to 6.4% (WHO)

The ADA and WHO use slightly different lower bounds for the fasting criterion. The ADA's 100 mg/dL threshold captures a broader, higher-risk population earlier.

Intensive lifestyle intervention is the first-line treatment. The landmark Diabetes Prevention Program (DPP) trial (N=3,234) demonstrated that structured lifestyle modification, targeting 7% body weight loss through 150 minutes per week of moderate activity, reduced progression to type 2 diabetes by 58% over 2.8 years compared to placebo [10]. That outcome eclipsed the metformin arm, which reduced progression by 31% [10]. The lifestyle intervention benefit was particularly strong in adults aged 60 and older, where it reduced progression by 71% [10].

Losing just 5% of body weight improves insulin sensitivity meaningfully. A 2020 study in The Journal of Clinical Endocrinology and Metabolism found that 5% weight loss in overweight adults with prediabetes reduced hepatic fat by 25% and restored first-phase insulin secretion by approximately 40% [11].

Can Metformin Reverse Prediabetes?

Metformin does not "reverse" prediabetes in the sense of permanently normalizing glucose metabolism, but it reduces the rate of conversion to type 2 diabetes and, in a subset of patients, brings glucose into the normal range while the drug is active. The DPP showed a 31% risk reduction for metformin 850 mg twice daily versus placebo over 2.8 years [10]. Long-term follow-up from the DPP Outcomes Study (DPPOS) confirmed sustained benefit at 15 years, with a 17% to 18% risk reduction for the metformin group [10].

Metformin works through three main mechanisms: it reduces hepatic glucose production, improves insulin sensitivity in skeletal muscle, and modestly delays intestinal glucose absorption. None of these mechanisms repairs the pancreatic beta-cell defect underlying prediabetes, which is why normoglycemia during metformin therapy is not the same as permanent remission [7].

The ADA recommends considering metformin for prediabetes in adults with BMI at or above 35 kg/m2, those aged <60, women with prior gestational diabetes, and anyone whose A1C is rising despite lifestyle efforts [1]. The standard dose is 500 mg twice daily titrated over 4 weeks to 1 to 000 mg twice daily, or the extended-release formulation at 1,500 to 2 to 000 mg once nightly, which reduces gastrointestinal side effects [7].

Metformin can lower A1C by 1.0% to 1.5% as monotherapy, placing it among the most effective oral agents per unit of hypoglycemia risk, which is near zero because it does not stimulate insulin secretion directly [1].

Newer agents are entering the prediabetes conversation. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) produce 10% to 15% weight loss and have shown A1C reductions of 1.0% to 1.8% in type 2 diabetes trials, though head-to-head data in prediabetes specifically are limited. The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed that semaglutide 2.4 mg reduced the rate of new-onset diabetes by 73% in people with obesity and established cardiovascular disease, a population heavily enriched with prediabetes at baseline [12].

How Often Should A1C Be Tested?

The ADA recommends A1C testing at least twice per year for people with diabetes who are meeting treatment goals and quarterly for those whose therapy has changed or who are not meeting targets [1]. For prediabetes screening in adults aged 35 to 70 with overweight or obesity, the U.S. Preventive Services Task Force (USPSTF) recommends screening every 3 years if results are normal and more frequently if A1C is in the prediabetes range [13].

Home A1C kits (such as A1CNow) provide results in about 5 minutes from a fingerstick. Their accuracy is within 0.3 to 0.4 percentage points of laboratory values in most validations, acceptable for monitoring but not recommended for diagnosis, which requires a laboratory-certified assay [1].

Factors that artificially lower A1C include hemolytic anemia, iron-deficiency anemia treatment with IV iron (which stimulates red cell turnover), and recent blood transfusion. Factors that artificially raise it include iron-deficiency anemia and vitamin B12 deficiency, both of which prolong red cell lifespan [2]. Clinicians should always interpret A1C alongside fasting glucose or CGM data when there is reason to suspect a discrepancy.

Lifestyle Factors That Move A1C the Most

Blood sugar control responds to diet, activity, sleep, and stress. Quantifying these effects helps prioritize effort.

Dietary pattern change produces the most immediate effect. A low-carbohydrate diet (below 130 g carbohydrate per day) reduces A1C by an average of 0.6% to 1.0% at 3 to 6 months compared to a standard diabetes diet, according to a 2017 Cochrane review of 18 trials [14]. The benefit narrows at 12 months as adherence declines, which is the primary limitation of any dietary intervention.

Aerobic exercise, 150 minutes per week at moderate intensity, reduces A1C by approximately 0.6% over 12 weeks as a standalone intervention [8]. Adding resistance training to aerobic training produces an additional 0.2% reduction [8].

Sleep deprivation is underappreciated as a blood sugar driver. A randomized crossover trial (N=14) published in Annals of Internal Medicine found that restricting sleep to 5.5 hours per night for 2 weeks reduced insulin sensitivity by 25% compared to 8.5 hours, independent of diet or activity [15]. Chronic partial sleep restriction may account for a meaningful share of A1C elevation in people who are otherwise adherent to diet and medication.

Stress raises cortisol, which raises glucose. A 2013 randomized trial of mindfulness-based stress reduction in adults with type 2 diabetes (N=60) showed a 0.5% reduction in A1C at 3 months compared to the control group [16].